Taipei, Taiwan, and Yokohama, Japan - August 21st, 2024 - Celltech Innovation Venture Studio Co., Ltd. (“CellTech Accelerator”), the first cell and gene therapy accelerator in Asia, and Minaris Regenerative Medicine Co., Ltd. ("Minaris"), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnership to accelerate the industrialization of Cell and Gene Therapies in Taiwan, Japan, and ASEAN countries.
This collaboration aims to support the practical application and advancement of regenerative medicine products developed by emerging bio-ventures. The partnership will provide these companies with essential resources, expertise, and opportunities to expand their innovations overseas. By combining CellTech Accelerator’s robust entrepreneurial ecosystem with Minaris’ world-class manufacturing capabilities, the alliance seeks to drive significant progress in the commercialization and global reach of cell and gene therapies.
Johnny Yu, Founder & Chairman of CellTech Accelerator, commented, “We are extremely excited to partner with Minaris, a company that shares our commitment to innovation and excellence in the cell and gene therapy industry. This collaboration represents a significant milestone in our mission to accelerate the development of transformative therapies. By combining our industrial acceleration capabilities with Minaris' expertise in manufacturing and development, we aim to streamline the path from discovery to delivery, ultimately bringing life-changing treatments to patients faster and more efficiently.”
Dr. Hiroto Bando, CEO of Minaris, added, “This strategic partnership with CellTech Accelerator is crucial to fulfilling our vision of Creating Future Cell Therapy Miracles Together. We will leverage our collective strengths to overcome the challenges of industrialization and ensure that innovative therapies reach patients in need. Our combined efforts will not only enhance the capabilities of emerging bio-ventures but also contribute to the growth and sustainability of the regenerative medicine industry as a whole.”
About CellTech Accelerator
CellTech Accelerator is the first startup accelerator in Asia solely focused on advancing the cell and gene therapy industry. It supports entrepreneurs in translating cell therapy technologies into practical applications by providing financial support, consulting, and commercialization training services. The company has established an entrepreneurial ecosystem and collaborates with investors and industry partners to drive technology commercialization. Additionally, it offers a comprehensive support system that addresses all aspects of growth for cell and gene therapy ventures.
For more information, please visit https://genecelltech.com/
About Minaris Regenerative Medicine Co., Ltd.
Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. Our vision is creating future cell therapy miracles together and we are committed to providing global manufacturing services, development solutions, and technologies for cell and gene therapies to improve society’s well-being. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 25 years’ experience providing outstanding quality and reliability. Our facilities in North America, Europe, and Asia allow us to supply patients worldwide with life-changing therapies. Minaris Regenerative Medicine is wholly owned by Resonac Holdings Corporation.
For more information, please visit https://www.rm.minaris.com/en/
CellTech Accelerator Media Contact:
Patryk Chojecki
Research Associate
Minaris Media Contact:
Yutaka Mitsuo
Head of Business Development Department